中新网上海3月14日电 (记者 陈静)视力受损是全球关注的健康问题，眼底病是不可逆致盲性眼病之一。中新网记者今日获悉，一种针对糖尿病黄斑水肿(DME)的创新药物在上海正式投入使用，为广大患者带来了希望的曙光。
糖尿病黄斑水肿是糖尿病患者常见的并发症之一，它会导致视力下降，甚至失明，严重影响患者的生活质量。这种创新药物通过抑制血管内皮生长因子(VEGF)的作用，可以减轻黄斑水肿，显著提高患者的视力。
据了解，该药物已经过严格的临床验证，并在多个国家和地区得到了应用，取得了良好的治疗效果。此次在上海的落地，将为上海及周边地区的糖尿病黄斑水肿患者提供更加便捷的治疗服务。
此外，医疗机构还将提供专业的用药指导和随访服务，以确保患者能够安全有效地使用该药物，并最大程度地提高治疗效果。
糖尿病黄斑水肿患者的福音：创新药物在上海正式投入使用。该药物通过抑制VEGF的作用，减轻黄斑水肿，显著提高患者视力。医疗机构提供专业用药指导和随访服务，确保患者安全有效使用。
英文标题：Innovative Drug for Diabetes Macular Edema Launches in Shanghai, Bringing Hope to Patients
英文关键词：Diabetic Macular Edema (DME), Innovative Drug, Vision Protection
英文新闻内容：
SHANGHAI, March 14 (Xinhua) — Visual impairment is a global health concern, and retinal diseases are irreversible causes of blindness. Xinhua News Agency reporter learned on Monday that an innovative drug for diabetic macular edema (DME) has been officially made available in Shanghai, offering new hope to patients.
DME is a common complication of diabetes that can lead to vision loss and even blindness, severely affecting patients’ quality of life. The innovative drug, which works by inhibiting the action of vascular endothelial growth factor (VEGF), can reduce macular edema and significantly improve patients’ vision.
The drug has undergone rigorous clinical trials and has been applied in many countries and regions with good results. Its launch in Shanghai will provide more convenient treatment services for patients with DME in the city and surrounding areas.
In addition, medical institutions will provide professional drug usage guidance and follow-up services to ensure that patients can use the drug safely and effectively, maximizing treatment outcomes.
【来源】http://www.chinanews.com/life/2024/03-14/10180295.shtml
Views: 1